Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy? A systematic review of randomised controlled trials

Abstract

Does antihypertensive treatment in normotensive patients with diabetic nephropathy alter the progression of kidney failure? We have evaluated studies of renal function which either assessed the effects of different therapeutic blood pressure (BP) goals, or the effects of antihypertensive therapy within the normotensive BP range. Need for renal replacement therapy was regarded as the most valid end point for assessment of deterioration of nephropathy, and change in the glomerular filtration rate (GFR) was regarded as a valid surrogate parameter. Five randomised controlled trials (RCTs) which included normotensive and hypertensive type 1 and type 2 diabetic patients have investigated the effect of lowering of BP within the normotensive range, or from hypertensive values to within the normotensive range. Albumin excretion in urine decreased in the groups randomised to lower BP values, but none of the trials demonstrated any beneficial effect of this intervention on the progression of kidney failure as assessed by the course of GFR. In conclusion, in diabetic patients with microalbuminuria or overt nephropathy, there is no evidence in the literature from RCTs for a beneficial effect of lowering BP within the normotensive range on the risk of kidney replacement therapy or on the loss of glomerular function.

Keywords

diabetic nephropathy blood pressure albuminuria glomerular filtration rate normotension hypertension.

Get full access to this article

View all access options for this article.

References

Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy . N Engl J Med 1993;329:1456-62.

Björck S. , Mulec H. , Johnsen SA , Norden G. , Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-42.

Bauer JH , Reams GP , Hewett J. et al. A randomised, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992;20:443-57.

Elving LD , Wetzels JMF , van Lier HJJ , de Nobel E. , Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994 ;37:604-09.

Parving HH , Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994 ;3:292-300.

Rossing P. , Tarnow L. , Boelskifte S. , Jensen BR , Nielsen FS , Parving HH Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997 ;46:481-7.

Sawicki PT Stabilisation of glomerular filtration rate over two years in patients with diabetic nephropathy and intensified therapy regimes. Nephrol Dial Transplant 1997;12:1890-9.

Hovind P. , Rossing P. , Tarnow L. , Smith UM , Parving HH Progression of diabetic nephropathy. Kidney Int 2001;59:702-09.

10.

Rossing P. , Hougaard P. , Parving HH Risk factors for development of incipient and overt nephropathy in Type 1 diabetic patients. Diabetes Care 2002 ;25:859-64.

11.

American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002;25(Suppl 1):S85-S89.

12.

Sign. Management of diabetic nephropathy. http://www.sign.ac.uk/guidelines/fulltext/55/section5.html (accessed 13 February 2003).

13.

Ramsay LE , Williams B. , Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.

14.

Sawicki PT , Berger M. Measuring progression of diabetic nephropathy. Review. Eur J Clin Invest 1994;24:651-5.

15.

Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003 ]. http://www.cochrane.de/cochrane/handbook/handbook.htm (accessed 13 February 2003).

16.

Jadad AR , Moore RA , Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.

17.

Schrier RW , Estacio RO , Esler A. , Mehler P. Effects of aggressive BP control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.

18.

Estacio RO , Jeffers BW , Gifford N. , Schrier RW Effect of BP control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.

19.

Lewis JB , Berl T. , Bain RP , Rohde RP , Lewis EJ Effect of intensive BP control on the course of type 1 diabetic nephropathy . Am J Kidney Dis 1999;34:809-17.

20.

Parving HH , Hommel E. , Jensen BR , Hansen HP Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34.

21.

Viberti G. , Mogensen CE , Groop LC , Pauls JF Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.

22.

Parving HH , Hommel E. , Damkjaer Nielsen M. , Giese J. Effect of captopril on BP and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989;299:533-6.